These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 24561043

  • 1. The dual PI3K/mTOR inhibitor NVP-BEZ235 prevents epithelial-mesenchymal transition induced by hypoxia and TGF-β1.
    Lin G, Gai R, Chen Z, Wang Y, Liao S, Dong R, Zhu H, Gu Y, He Q, Yang B.
    Eur J Pharmacol; 2014 Apr 15; 729():45-53. PubMed ID: 24561043
    [Abstract] [Full Text] [Related]

  • 2. Growth inhibition by NVP-BEZ235, a dual PI3K/mTOR inhibitor, in hepatocellular carcinoma cell lines.
    Masuda M, Shimomura M, Kobayashi K, Kojima S, Nakatsura T.
    Oncol Rep; 2011 Nov 15; 26(5):1273-9. PubMed ID: 21725613
    [Abstract] [Full Text] [Related]

  • 3. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
    Yu Z, Xie G, Zhou G, Cheng Y, Zhang G, Yao G, Chen Y, Li Y, Zhao G.
    Cancer Lett; 2015 Oct 10; 367(1):58-68. PubMed ID: 26188279
    [Abstract] [Full Text] [Related]

  • 4. Dual blockade of PI3K/AKT/mTOR (NVP-BEZ235) and Ras/Raf/MEK (AZD6244) pathways synergistically inhibit growth of primary endometrioid endometrial carcinoma cultures, whereas NVP-BEZ235 reduces tumor growth in the corresponding xenograft models.
    Schrauwen S, Depreeuw J, Coenegrachts L, Hermans E, Lambrechts D, Amant F.
    Gynecol Oncol; 2015 Jul 10; 138(1):165-73. PubMed ID: 25933683
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma.
    Doghman M, Lalli E.
    Mol Cell Endocrinol; 2012 Nov 25; 364(1-2):101-4. PubMed ID: 22960230
    [Abstract] [Full Text] [Related]

  • 6. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
    Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, Botero ML, Llonch E, Atzori F, Di Cosimo S, Maira M, Garcia-Echeverria C, Parra JL, Arribas J, Baselga J.
    Cancer Res; 2008 Oct 01; 68(19):8022-30. PubMed ID: 18829560
    [Abstract] [Full Text] [Related]

  • 7. NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate.
    Gobin B, Battaglia S, Lanel R, Chesneau J, Amiaud J, Rédini F, Ory B, Heymann D.
    Cancer Lett; 2014 Mar 28; 344(2):291-8. PubMed ID: 24333720
    [Abstract] [Full Text] [Related]

  • 8. The PI3K/mTOR dual inhibitor NVP-BEZ235 reduces the growth of ovarian clear cell carcinoma.
    Oishi T, Itamochi H, Kudoh A, Nonaka M, Kato M, Nishimura M, Oumi N, Sato S, Naniwa J, Sato S, Shimada M, Kigawa J, Harada T.
    Oncol Rep; 2014 Aug 28; 32(2):553-8. PubMed ID: 24927217
    [Abstract] [Full Text] [Related]

  • 9. Inhibition of Autophagy Increases Proliferation Inhibition and Apoptosis Induced by the PI3K/mTOR Inhibitor NVP-BEZ235 in Breast Cancer Cells.
    Ji Y, Di W, Yang Q, Lu Z, Cai W, Wu J.
    Clin Lab; 2015 Aug 28; 61(8):1043-51. PubMed ID: 26427150
    [Abstract] [Full Text] [Related]

  • 10. Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.
    Fuereder T, Wanek T, Pflegerl P, Jaeger-Lansky A, Hoeflmayer D, Strommer S, Kuntner C, Wrba F, Werzowa J, Hejna M, Müller M, Langer O, Wacheck V.
    Clin Cancer Res; 2011 Aug 15; 17(16):5322-32. PubMed ID: 21712451
    [Abstract] [Full Text] [Related]

  • 11. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma.
    Zhu YR, Min H, Fang JF, Zhou F, Deng XW, Zhang YQ.
    Cancer Biol Ther; 2015 Aug 15; 16(4):602-9. PubMed ID: 25869769
    [Abstract] [Full Text] [Related]

  • 12. The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.
    Brünner-Kubath C, Shabbir W, Saferding V, Wagner R, Singer CF, Valent P, Berger W, Marian B, Zielinski CC, Grusch M, Grunt TW.
    Breast Cancer Res Treat; 2011 Sep 15; 129(2):387-400. PubMed ID: 21046231
    [Abstract] [Full Text] [Related]

  • 13. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
    Yasumizu Y, Miyajima A, Kosaka T, Miyazaki Y, Kikuchi E, Oya M.
    J Urol; 2014 Jan 15; 191(1):227-34. PubMed ID: 23954373
    [Abstract] [Full Text] [Related]

  • 14. Intravesical dual PI3K/mTOR complex 1/2 inhibitor NVP-BEZ235 therapy in an orthotopic bladder cancer model.
    Matsushima M, Kikuchi E, Matsumoto K, Hattori S, Takeda T, Kosaka T, Miyajima A, Oya M.
    Int J Oncol; 2015 Jul 15; 47(1):377-83. PubMed ID: 25963317
    [Abstract] [Full Text] [Related]

  • 15. Dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 synergizes with chloroquine to induce apoptosis in embryonal rhabdomyosarcoma.
    Hugle M, Fulda S.
    Cancer Lett; 2015 Apr 28; 360(1):1-9. PubMed ID: 25637161
    [Abstract] [Full Text] [Related]

  • 16. The dual PI3K and mTOR inhibitor NVP-BEZ235 exhibits anti-proliferative activity and overcomes bortezomib resistance in mantle cell lymphoma cells.
    Kim A, Park S, Lee JE, Jang WS, Lee SJ, Kang HJ, Lee SS.
    Leuk Res; 2012 Jul 28; 36(7):912-20. PubMed ID: 22560334
    [Abstract] [Full Text] [Related]

  • 17. Dual inhibition of phosphatidylinositol 3'-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach for mucinous adenocarcinoma of the ovary.
    Kudoh A, Oishi T, Itamochi H, Sato S, Naniwa J, Sato S, Shimada M, Kigawa J, Harada T.
    Int J Gynecol Cancer; 2014 Mar 28; 24(3):444-53. PubMed ID: 24552895
    [Abstract] [Full Text] [Related]

  • 18. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
    Li H, Jin X, Zhang Z, Xing Y, Kong X.
    Cell Biochem Funct; 2013 Jul 28; 31(5):427-33. PubMed ID: 23086777
    [Abstract] [Full Text] [Related]

  • 19. Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer.
    Kim A, Lee JE, Lee SS, Kim C, Lee SJ, Jang WS, Park S.
    Int J Cancer; 2013 Aug 15; 133(4):984-96. PubMed ID: 23475782
    [Abstract] [Full Text] [Related]

  • 20. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced.
    Jebahi A, Villedieu M, Pétigny-Lechartier C, Brotin E, Louis MH, Abeilard E, Giffard F, Guercio M, Briand M, Gauduchon P, Lheureux S, Poulain L.
    Cancer Lett; 2014 Jun 28; 348(1-2):38-49. PubMed ID: 24650799
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.